Literature DB >> 373087

IgG-, IgM- and IgA-rheumatoid factors in healthy adults and rheumatoid patients determined by an indirect immunofluorescence method.

H E Kallerup, E M Egeskjold, H Graudal.   

Abstract

Sera from 173 healthy adults and 55 rheumatoid patients were studied for IgG-, IgM- and IgA-rheumatoid factors (RFs) by a modification of Este's indirect immunofluorescence method. Rabbit IgG bound to smeared sheep red cells was used as antigen. With each serum tested a smear on non-sensitized cells was used as control antigen. Anti-IgG of the sera studied, binding to the antigen, was demonstrated by fluorescein-conjugated antisera, monospecific for gamma, mu and alpha chains, and not containing antibodies to sheep erythrocytes or rabbit IgG. Positive reactions were obtained with IgG as antigen, but not with the F(ab')2 fragment. The sera tested were treated with dithiothreitol before they were assayed for IgG-RF, in order to abolish false-positive reactions due to IgM-RF activity. The detection limit for IgM-RF was 1 IU per ml. IgM-RF titres of 9 occurred in 7% of healthy adults and 73% of rheumatoid patients, titres greater than or equal to 18 in 3.5% and 67% respectively. IgG-RF titres of 9 occurred in 9% of healthy adults, 21% of seronegative and 24% of seropositive rheumatoid patients. Titres of 18 occurred in 3% of healthy adults and in 14% of seronegative rheumatoid patients. Titres of greater than or equal to 18 occurred in 22% of seropositive rheumatoid patients. IgG-RF was correlated with an involvement of more than 20 joints. IgA-RF was found in 83% of seropositive, 11% of seronegative rheumatoid patients and in none of the healthy adults (serum dilution 1:9).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 373087

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  12 in total

1.  Autoantibodies as diagnostic tool in juvenile connective tissue diseases.

Authors:  E M Egeskjold
Journal:  Indian J Pediatr       Date:  1989 May-Jun       Impact factor: 1.967

2.  Clinical value of ELISA assays for IgM and IgG rheumatoid factors.

Authors:  R Stone; J S Coppock; P T Dawes; P A Bacon; D L Scott
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

3.  HLA-DR4 does not predispose to higher amounts of rheumatoid factors in healthy persons.

Authors:  T L Vischer; V Von Fliedner
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

4.  Measurement of rheumatoid factors by an enzyme-linked immunosorbent assay (ELISA) and comparison with other methods.

Authors:  J L Bampton; T E Cawston; M V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

5.  Evidence for relationships between antiperinuclear and IgG rheumatoid factor.

Authors:  P Youinou; P Le Goff; R Casburn-Budd; C Ferec; Y Pennec
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

6.  Clinical and immunogenetic studies in rheumatoid arthritis from northern India.

Authors:  A N Malaviya; N K Mehra; B Dasgupta; K M Khan; U R Rao; A Agarwal; S C Tiwari
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

7.  IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis.

Authors:  M Gioud-Paquet; M Auvinet; T Raffin; P Girard; M Bouvier; E Lejeune; J C Monier
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

8.  IgG rheumatoid factors and anti-nuclear antibodies in rheumatoid vasculitis.

Authors:  F P Quismorio; T Beardmore; R L Kaufman; E S Mongan
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

9.  Immunoglobulin E-rheumatoid factor in the serum of patients with rheumatoid arthritis, asthma, and other diseases.

Authors:  B L Zuraw; C H O'Hair; J H Vaughan; D A Mathison; J G Curd; D H Katz
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

10.  Clinical relevance of antikeratin antibodies in rheumatoid arthritis.

Authors:  P Miossec; P Youinou; P Le Goff; M P Moineau
Journal:  Clin Rheumatol       Date:  1982-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.